FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996930819> ?p ?o ?g. }

• W1996930819 endingPage "762" @default.
• W1996930819 startingPage "761" @default.
• W1996930819 abstract "Background/objectives Alumtzumab is approved in over 30 countries for relapsing-remitting multiple sclerosis. In the 2-year, phase 3 CARE-MS I study (NCT00530348), Alemtuzumab significantly reduced relapses compared with subcutaneous interferon beta-1a, with manageable safety in treatment-naive patients with active relapsing-remitting multiple sclerosis. Durable efficacy of Alemtuzumab was demonstrated at 3-year follow-up. Here we report results for years 3 and 4 after Alemtuzumab initiation, and for years 1 and 2 after Alemtuzumab initiation in patients initially treated with subcutaneous interferon beta-1a (crossover cohort). Design and methods In CARE-MS I, patients received Alemtuzumab (12 mg/day intravenously on 5 consecutive days and on 3 consecutive days 12 months later) or subcutaneous interferon beta-1a (44 μg 3 times/week). In the extension study (NCT00930553), patients could receive as-needed Alemtuzumab re-treatment (12 mg/day on 3 consecutive days) ≥1 year apart or other disease-modifying therapy. Crossover patients received 2 Alemtuzumab courses (5 days then 3 days) 12 months apart. Results The extension enrolled 349 (95%) eligible patients from the core study Alemtuzumab arm. Through 4 years, 73% of these patients received only 2 annual courses, while 21% and 5% received 1 or 2 additional courses, respectively; <5% of patients received another disease-modifying therapy during the extension. Nine patients (3%) discontinued from the study, none due to adverse events. Among patients who received subcutaneous interferon beta-1a in CARE-MS I, 144 (83%) entered the extension and 132 (92%) received 2 courses of Alemtuzumab. There were 8 withdrawals (6%) in the crossover group during the 2-year extension period, none due to adverse events. Efficacy and safety data will be reported. Conclusions Most patients receiving Alemtuzumab during the core study required no re-treatment during the 2-year extension period; few sought alternative therapies or withdrew from the study. Among crossover patients, most received both treatment courses and remained in the study. Alumtzumab is approved in over 30 countries for relapsing-remitting multiple sclerosis. In the 2-year, phase 3 CARE-MS I study (NCT00530348), Alemtuzumab significantly reduced relapses compared with subcutaneous interferon beta-1a, with manageable safety in treatment-naive patients with active relapsing-remitting multiple sclerosis. Durable efficacy of Alemtuzumab was demonstrated at 3-year follow-up. Here we report results for years 3 and 4 after Alemtuzumab initiation, and for years 1 and 2 after Alemtuzumab initiation in patients initially treated with subcutaneous interferon beta-1a (crossover cohort). In CARE-MS I, patients received Alemtuzumab (12 mg/day intravenously on 5 consecutive days and on 3 consecutive days 12 months later) or subcutaneous interferon beta-1a (44 μg 3 times/week). In the extension study (NCT00930553), patients could receive as-needed Alemtuzumab re-treatment (12 mg/day on 3 consecutive days) ≥1 year apart or other disease-modifying therapy. Crossover patients received 2 Alemtuzumab courses (5 days then 3 days) 12 months apart. The extension enrolled 349 (95%) eligible patients from the core study Alemtuzumab arm. Through 4 years, 73% of these patients received only 2 annual courses, while 21% and 5% received 1 or 2 additional courses, respectively; <5% of patients received another disease-modifying therapy during the extension. Nine patients (3%) discontinued from the study, none due to adverse events. Among patients who received subcutaneous interferon beta-1a in CARE-MS I, 144 (83%) entered the extension and 132 (92%) received 2 courses of Alemtuzumab. There were 8 withdrawals (6%) in the crossover group during the 2-year extension period, none due to adverse events. Efficacy and safety data will be reported. Most patients receiving Alemtuzumab during the core study required no re-treatment during the 2-year extension period; few sought alternative therapies or withdrew from the study. Among crossover patients, most received both treatment courses and remained in the study." @default.
• W1996930819 created "2016-06-24" @default.
• W1996930819 creator A5020016996 @default.
• W1996930819 creator A5028522005 @default.
• W1996930819 creator A5045037633 @default.
• W1996930819 creator A5051127501 @default.
• W1996930819 creator A5062032887 @default.
• W1996930819 creator A5069727178 @default.
• W1996930819 creator A5078067575 @default.
• W1996930819 creator A5078101216 @default.
• W1996930819 creator A5088675402 @default.
• W1996930819 date "2014-11-01" @default.
• W1996930819 modified "2023-09-29" @default.
• W1996930819 title "Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study" @default.
• W1996930819 doi "https://doi.org/10.1016/j.msard.2014.09.207" @default.
• W1996930819 hasPublicationYear "2014" @default.
• W1996930819 type Work @default.
• W1996930819 sameAs 1996930819 @default.
• W1996930819 citedByCount "2" @default.
• W1996930819 countsByYear W19969308192015 @default.
• W1996930819 countsByYear W19969308192017 @default.
• W1996930819 crossrefType "journal-article" @default.
• W1996930819 hasAuthorship W1996930819A5020016996 @default.
• W1996930819 hasAuthorship W1996930819A5028522005 @default.
• W1996930819 hasAuthorship W1996930819A5045037633 @default.
• W1996930819 hasAuthorship W1996930819A5051127501 @default.
• W1996930819 hasAuthorship W1996930819A5062032887 @default.
• W1996930819 hasAuthorship W1996930819A5069727178 @default.
• W1996930819 hasAuthorship W1996930819A5078067575 @default.
• W1996930819 hasAuthorship W1996930819A5078101216 @default.
• W1996930819 hasAuthorship W1996930819A5088675402 @default.
• W1996930819 hasConcept C126322002 @default.
• W1996930819 hasConcept C141071460 @default.
• W1996930819 hasConcept C197934379 @default.
• W1996930819 hasConcept C203014093 @default.
• W1996930819 hasConcept C2779015954 @default.
• W1996930819 hasConcept C2780640218 @default.
• W1996930819 hasConcept C2908698914 @default.
• W1996930819 hasConcept C2911091166 @default.
• W1996930819 hasConcept C2994247566 @default.
• W1996930819 hasConcept C3020694758 @default.
• W1996930819 hasConcept C71924100 @default.
• W1996930819 hasConceptScore W1996930819C126322002 @default.
• W1996930819 hasConceptScore W1996930819C141071460 @default.
• W1996930819 hasConceptScore W1996930819C197934379 @default.
• W1996930819 hasConceptScore W1996930819C203014093 @default.
• W1996930819 hasConceptScore W1996930819C2779015954 @default.
• W1996930819 hasConceptScore W1996930819C2780640218 @default.
• W1996930819 hasConceptScore W1996930819C2908698914 @default.
• W1996930819 hasConceptScore W1996930819C2911091166 @default.
• W1996930819 hasConceptScore W1996930819C2994247566 @default.
• W1996930819 hasConceptScore W1996930819C3020694758 @default.
• W1996930819 hasConceptScore W1996930819C71924100 @default.
• W1996930819 hasIssue "6" @default.
• W1996930819 hasLocation W19969308191 @default.
• W1996930819 hasOpenAccess W1996930819 @default.
• W1996930819 hasPrimaryLocation W19969308191 @default.
• W1996930819 hasRelatedWork W1969129043 @default.
• W1996930819 hasRelatedWork W2260535563 @default.
• W1996930819 hasRelatedWork W2552209029 @default.
• W1996930819 hasRelatedWork W2736093189 @default.
• W1996930819 hasRelatedWork W2766507203 @default.
• W1996930819 hasRelatedWork W2799976979 @default.
• W1996930819 hasRelatedWork W4233557523 @default.
• W1996930819 hasRelatedWork W4253883570 @default.
• W1996930819 hasRelatedWork W4256054669 @default.
• W1996930819 hasRelatedWork W4298162344 @default.
• W1996930819 hasVolume "3" @default.
• W1996930819 isParatext "false" @default.
• W1996930819 isRetracted "false" @default.
• W1996930819 magId "1996930819" @default.
• W1996930819 workType "article" @default.